A panel of advisers for the Facilities for Illness Management and Prevention (CDC) will meet on Thursday to think about whether or not to impose restrictions on the Johnson & Johnson COVID-19 vaccine as a consequence of new knowledge on uncommon blood clot points, The Washington Submit reported.
The Submit, citing clinicians acquainted with the assembly’s agenda, reported that the Advisory Committee on Immunization Practices will obtain data indicating that blood clot charges have risen, notably in youthful girls, although the problem stays extraordinarily uncommon.
One federal official advised the newspaper that 9 individuals have died as a consequence of blood clotting problems associated to the vaccine.
Earlier studies confirmed that not less than 4 individuals had died from the problems related to the corporate’s vaccine. Based on the Meals and Drug Administration, girls between the age of 30 and 49 years outdated have reported the best charge of blood clotting points, the Submit famous.
“We’re dedicated to understanding and speaking all identified dangers, together with uncommon occasions of [the blood clot condition], and strongly assist elevating consciousness of the indicators and signs of this uncommon occasion,” Johnson & Johnson spokesperson, Jake Sargent, advised The Submit in an e mail.
One clinician who spoke with the newspaper mentioned that advisors might both suggest the vaccine to be used for sure populations, cease utilizing it altogether or preserve its present advice unchanged — strategies that which can be topic to closing sign-off by CDC Director Rochelle Walensky
Rochelle WalenskyBiden marks 800K COVID-19 deaths by urging Individuals to get vaccinated CDC estimates omicron now 3 % of US COVID-19 circumstances The Hill’s Morning Report – Offered by Constitution Communications – Manchin not prepared but; Meadows texts unveiled MORE.
A preferential advice may be adopted as one other answer, during which Moderna and Pfizer-BioNTech vaccines are beneficial over the Johnson & Johnson vaccine, a federal official advised the Journal.
Use of the Johnson & Johnson vaccine was briefly halted within the U.S. earlier this 12 months. In April, nevertheless, the vaccine was allowed to be administered once more after officers decided that the advantages outweighed potential dangers.
The Hill has reached out to the CDC and J&J for remark.
